首页> 外文期刊>Gynecologic Oncology Reports >Aspirin use correlates with survival in women with clear cell ovarian cancer
【24h】

Aspirin use correlates with survival in women with clear cell ovarian cancer

机译:阿司匹林的使用与透明细胞卵巢癌妇女的生存相关

获取原文
           

摘要

Data from colon, breast and prostate cancers suggest that aspirin users have reduced mortality. While the direct mechanism remains uncertain, aspirin can suppress the COX-dependent and independent pathways involved in tumor progression. We hypothesized that aspirin users with clear cell ovarian cancer would have improved survival outcomes. We performed a retrospective review of patients with clear cell ovarian cancer diagnosed between 1995 and 2010, and followed outcomes through 2016. Patients underwent primary cytoreductive surgery followed by platinum-based chemotherapy. Aspirin use was defined by medication documentation in two records more than six months apart. Statistical tests included Fisher's exact, Kaplan-Meier and Cox regression analyses. Seventy-seven patients met inclusion criteria. Fifty-four patients (70%) had stage I-II disease. Thirteen patients (17%) used aspirin. Aspirin users had a statistically longer disease-free survival compared to non-users (HR 0.13, p ?=?.018). While median disease-free survival was not reached for either group, 1 of 13 (8%) aspirin users recurred at 24 months, compared to 18 of 64 (28%) non-users. Aspirin users demonstrated longer overall survival (HR 0.13, p ?=?.015). Median survival was not reached for aspirin users, compared to 166?months for non-users. Aspirin use retained significance (HR 0.13, p ?=?.044) after controlling for age, stage and cytoreductive status. In this small cohort of women with clear cell ovarian cancer, aspirin use correlated with improved disease-free and overall survival, and retained independent significance as a positive prognostic factor. Further research is warranted to confirm these findings before considering aspirin as a therapeutic intervention. Highlights ? Research indicates that aspirin use may reduce mortality in various malignancies. ? Improved survival may be related to inhibition of COX-dependent pathways, particularly for PIK3CA mutation carriers. ? We retrospectively evaluated the relationship between aspirin use and survival in 77 women with clear cell ovarian cancer. ? Aspirin was independently associated with improved disease-free and overall survival.
机译:来自结肠癌,乳腺癌和前列腺癌的数据表明,服用阿司匹林的人降低了死亡率。虽然直接机制仍不确定,但是阿司匹林可以抑制肿瘤进展中涉及的COX依赖和独立途径。我们假设患有透明细胞卵巢癌的阿司匹林使用者将改善生存结果。我们对1995年至2010年间诊断为透明细胞卵巢癌的患者进行了回顾性研究,并随访了直至2016年的结果。患者接受了原发性细胞减灭术,然后进行了铂类化学疗法。阿司匹林的使用由药物文献定义,相隔六个月以上,有两个记录。统计检验包括Fisher的精确,Kaplan-Meier和Cox回归分析。 77名患者符合纳入标准。 54名患者(70%)患有I-II期疾病。 13名患者(17%)使用了阿司匹林。与非使用者相比,阿司匹林使用者的无病生存期在统计上更长(HR 0.13,p?= ?. 018)。尽管两组均未达到中位无病生存期,但13名阿司匹林使用者中有1名在24个月时复发,而64名非使用者中有18名(28%)复发。阿司匹林使用者显示出更长的总生存期(HR 0.13,p?= ?. 015)。阿司匹林使用者未达到中位生存期,非使用者则为166个月。在控制年龄,分期和细胞减少状态后,阿司匹林的使用仍具有重要意义(HR 0.13,p <=。044)。在这个患有透明细胞卵巢癌的女性小队列中,阿司匹林的使用与无病生存期和总体生存期相关,并且作为积极的预后因素仍具有独立的意义。在考虑将阿司匹林作为治疗干预措施之前,有必要进行进一步的研究来证实这些发现。强调 ?研究表明,使用阿司匹林可以降低各种恶性肿瘤的死亡率。 ?存活率的提高可能与抑制COX依赖性途径有关,尤其是对PIK3CA突变携带者而言。 ?我们回顾性评估了77名透明细胞卵巢癌妇女中阿司匹林使用与生存之间的关系。 ?阿司匹林与改善无病生存率和总体生存率独立相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号